Home > Insider Trading > Filing (0001209191-19-054503)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1510487	Principia Biopharma Inc.	PRNB	Pharmaceutical Preparations (2834)	263487603

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1752139	J. Daniel Becker	C/O Principia Biopharma Inc. 220 E. Grand Avenue South San Francisco CA 94080		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-10-28	68,404	$33.41	603,404	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2019-10-29	9,196	$33.98	612,600	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Footnotes

Price represents the weighted average price of the shares purchased. The purchase price ranged from $32.66 to $33.65 per share. Upon request by the Commission staff, the Issuer or the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The Reporting Person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein.
Price represents the weighted average price of the shares purchased. The purchase price ranged from $33.50 to $34.00 per share. Upon request by the Commission staff, the Issuer or the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.